Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза IV Россия

LY275585 (Инсулин лизпро, Хумалог)

Два подхода к интенсификации терапии с помощью инсулина лизпро у пациентов с сахарным диабетом 2 типа, не достигших адекватного гликемического контроля на терапии базальным инсулином в сочетании с пероральными препаратами (AUTONOMY).

Разрешение№ 94 от 01.03.2011
Номер протоколаF3Z-MC-IOQC
ФазаФаза IV
Участников по плану110
Сроки02.03.2011 — 31.05.2013
Страна разработчикаСША
Начало: 2 марта 2011Окончание: 31 мая 2013
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/94/2011-03-01/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда

Простыми словами

Словарь терминов
  • Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–85 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 110 чел. в стране «Россия».
  • Центров в реестре: 7 в 5 городах. Список — ниже на странице.
  • Плановая дата окончания (05.2013) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–85 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 16

Критерии включения

  • Have type 2 diabetes
  • Have been treated for at least 90 days with insulin glargine, neutral protamine Hagedorn (NPH), or detemir in combination with oral antihyperglycemic agents as monotherapy, dual, or triple therapy \[sulfonylurea, meglitinide, metformin, pioglitazone, or dipeptidyl peptidase-4 (DPP-4) inhibitor\] and in the opinion of the investigator requires further intensification of therapy
  • Are treated with insulin glargine, NPH, or detemir at least 20 units per day (U/day) at enrollment
  • Have an glycated hemoglobin (HbA1c) value greater than 7.0% and less than or equal to 12.0% according to the central laboratory at screening
  • Capable of and willing to do the following: inject insulin with a prefilled pen, perform self blood glucose monitoring and record keeping as required by this protocol, as determined by the investigator
  • Have given written informed consent to participate in this study in accordance with local regulations

Критерии невключения

  • Prior rapid- or short-acting insulin therapy: participants receiving scheduled long-term short-acting or rapid-acting or premixed insulin therapy within the past 6 months will not be eligible to participate in the study. Participants who have previously received short- or rapid-acting insulin as part of short-term insulin therapy (during gestational diabetes, during an acute hospitalization or illness) or occasional use will be allowed to participate in this study. Occasional use (e.g., used to treat acute hyperglycemia) shall be defined as less than daily administration of not more than 1 dose per day of short- or rapid-acting insulin
  • Concomitant medications: glucagon-like peptide-1 (GLP-1) receptor agonist, alpha-glucosidase inhibitor, or rosiglitazone use concurrently or within 3 months prior to entry into the study
  • Severe hypoglycemia: have had more than one episode of severe hypoglycemia (defined as requiring assistance of a third party due to disabling hypoglycemia) within 6 months prior to entry into the study
  • Excessive insulin resistance: received a total daily dose of insulin greater than 2.0 units per kilogram (U/kg) at the time of randomization
  • Morbid obesity: defined as a body mass index greater than or equal to 45 kilograms per square meter (kg/m²)
  • Malignancy: have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years
  • Cardiovascular: have cardiac disease with functional status that is New York Heart Association Class III or IV (see New York Heart Association Cardiac Disease Classifications) or have Congestive Heart Failure (CHF) requiring pharmacologic treatment or, in the investigator's opinion, have severe dependent edema (i.e., edema of the feet or ankles) or have any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis
  • Renal: have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine greater than or equal to 2 milligrams per deciliter (mg/dL) if not on metformin
  • Hepatic: have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) greater than 3 times the upper limit of the reference range as defined by the central laboratory
  • Hematologic: have known hemoglobinopathy or chronic anemia or other known blood disorder
  • Reproductive:(for women) are pregnant or intend to become pregnant during the course of the study; are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable; or are breastfeeding
  • Allergy: have known allergy to insulin lispro, insulin glargine, or excipients contained in these products
  • Glucocorticoid therapy: receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately before screening
  • Adherence to protocol: have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes the participant from following and completing the protocol
  • Prior participation: are currently enrolled in, or have participated in, an interventional medical, surgical, or pharmaceutical drug or device or off-label use study (an investigational study in which a medical or surgical treatment was given) within 30 days prior to entry into the study, or persons who have previously completed or withdrawn from this study (after having signed the informed consent document). Participants may be ineligible if they are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Non-approved drug: have been treated with a drug within the last 30 days that has not received regulatory approval at the time of study entry

Источник: ClinicalTrials.gov, NCT01215955 · запись обновлена в реестре 23 апреля 2014.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Включено участников (факт, все страны)1 117
Что измеряют — первичные конечные точки (1), вторичных — 14
  • Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c) — Baseline, 24 weeks

Цель исследования

Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on basal insulin.

Области и заболевания

Где проходит

7 центров в 5 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.